Evolent Health Stock Buy Hold or Sell Recommendation
| EVH Stock | USD 9.41 0.13 1.36% |
Considering the 90-day investment horizon and your above-average risk tolerance, our recommendation regarding Evolent Health is 'Sell'. The recommendation algorithm takes into account all of Evolent Health's available fundamental, technical, and predictive indicators you will find on this site.
Check out Evolent Health Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more detail on how to invest in Evolent Stock please use our How to Invest in Evolent Health guide. In addition, we conduct extensive research on individual companies such as Evolent and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Evolent Health. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
Evolent |
Execute Evolent Health Buy or Sell Advice
The Evolent recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Evolent Health. Macroaxis does not own or have any residual interests in Evolent Health or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Evolent Health's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Sell
Market Performance | Very Weak | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Evolent Health Trading Alerts and Improvement Suggestions
| Evolent Health generated a negative expected return over the last 90 days | |
| Evolent Health has high historical volatility and very poor performance | |
| The company reported the last year's revenue of 2.55 B. Reported Net Loss for the year was (61.62 M) with profit before taxes, overhead, and interest of 367.35 M. | |
| Over 97.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: Q4 Earnings Review Healthcare Technology for Providers Stocks Led by Phreesia |
Evolent Health Returns Distribution Density
The distribution of Evolent Health's historical returns is an attempt to chart the uncertainty of Evolent Health's future price movements. The chart of the probability distribution of Evolent Health daily returns describes the distribution of returns around its average expected value. We use Evolent Health price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Evolent Health returns is essential to provide solid investment advice for Evolent Health.
| Mean Return | -0.2 | Value At Risk | -8.15 | Potential Upside | 4.41 | Standard Deviation | 3.43 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Evolent Health historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Evolent Stock Institutional Investors
| Shares | Jpmorgan Chase & Co | 2024-12-31 | 3.2 M | State Street Corp | 2024-12-31 | 3 M | Dimensional Fund Advisors, Inc. | 2024-12-31 | 2.9 M | Geode Capital Management, Llc | 2024-12-31 | 2.5 M | Boston Partners Global Investors, Inc | 2024-12-31 | 2.4 M | Rock Springs Capital Management Lp | 2024-12-31 | 2.1 M | Ubs Group Ag | 2024-12-31 | 1.8 M | Blair William & Co | 2024-12-31 | 1.7 M | Bank Of New York Mellon Corp | 2024-12-31 | 1.4 M | Vanguard Group Inc | 2024-12-31 | 11.2 M | Wellington Management Company Llp | 2024-12-31 | 10.4 M |
Evolent Health Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 233.1M | (6.6M) | (139.8M) | 8.3M | (45.0M) | (42.7M) | |
| Free Cash Flow | (45.7M) | 13.8M | (49.9M) | 113.8M | (6.1M) | (6.4M) | |
| Depreciation | 61.5M | 60.0M | 67.2M | 123.4M | 118.4M | 124.3M | |
| Other Non Cash Items | 298.4M | 13.8M | 10.5M | 101.1M | 41.8M | 42.3M | |
| Capital Expenditures | 29.5M | 25.0M | 38.4M | 28.7M | 24.9M | 25.0M | |
| Net Income | (334.2M) | (37.6M) | (19.2M) | (113.0M) | (61.6M) | (64.7M) | |
| End Period Cash Flow | 361.6M | 354.9M | 215.2M | 223.5M | 178.5M | 215.5M | |
| Change To Inventory | (19.5M) | 47.0M | (14.1M) | (10.7M) | (9.7M) | (9.2M) | |
| Investments | (10.1M) | 54.2M | 36.5M | (413.9M) | (62.9M) | (66.1M) | |
| Net Borrowings | (41.6M) | 13.5M | (98.8M) | 219.7M | 197.8M | 207.7M | |
| Change To Netincome | 187.9M | 277.8M | 17.0M | (26.9M) | (31.0M) | (29.4M) | |
| Dividends Paid | 20M | 1.3M | 14.9M | 18.8M | 20.1M | 16.6M |
Evolent Health Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Evolent Health or Health Care Technology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Evolent Health's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Evolent stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.18 | |
β | Beta against Dow Jones | 0.23 | |
σ | Overall volatility | 3.42 | |
Ir | Information ratio | -0.03 |
Evolent Health Volatility Alert
Evolent Health exhibits very low volatility with skewness of -1.03 and kurtosis of 1.87. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Evolent Health's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Evolent Health's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Evolent Health Fundamentals Vs Peers
Comparing Evolent Health's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Evolent Health's direct or indirect competition across all of the common fundamentals between Evolent Health and the related equities. This way, we can detect undervalued stocks with similar characteristics as Evolent Health or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Evolent Health's fundamental indicators could also be used in its relative valuation, which is a method of valuing Evolent Health by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Evolent Health to competition |
| Fundamentals | Evolent Health | Peer Average |
| Return On Equity | -0.0506 | -0.31 |
| Return On Asset | 6.0E-4 | -0.14 |
| Profit Margin | (0.02) % | (1.27) % |
| Operating Margin | (0.0009) % | (5.51) % |
| Current Valuation | 1.71 B | 16.62 B |
| Shares Outstanding | 116.59 M | 571.82 M |
| Shares Owned By Insiders | 2.71 % | 10.09 % |
| Shares Owned By Institutions | 97.29 % | 39.21 % |
| Number Of Shares Shorted | 14.2 M | 4.71 M |
| Price To Earning | (13.88) X | 28.72 X |
| Price To Book | 1.10 X | 9.51 X |
| Price To Sales | 0.43 X | 11.42 X |
| Revenue | 2.55 B | 9.43 B |
| Gross Profit | 367.35 M | 27.38 B |
| EBITDA | 80.06 M | 3.9 B |
| Net Income | (61.62 M) | 570.98 M |
| Cash And Equivalents | 188.2 M | 2.7 B |
| Cash Per Share | 1.57 X | 5.01 X |
| Total Debt | 223.15 M | 5.32 B |
| Debt To Equity | 0.56 % | 48.70 % |
| Current Ratio | 1.03 X | 2.16 X |
| Book Value Per Share | 8.70 X | 1.93 K |
| Cash Flow From Operations | 18.77 M | 971.22 M |
| Short Ratio | 5.68 X | 4.00 X |
| Earnings Per Share | (0.81) X | 3.12 X |
| Price To Earnings To Growth | (1.37) X | 4.89 X |
| Target Price | 15.46 | |
| Number Of Employees | 4.5 K | 18.84 K |
| Beta | 1.49 | -0.15 |
| Market Capitalization | 1.1 B | 19.03 B |
| Total Asset | 2.54 B | 29.47 B |
| Retained Earnings | (780.82 M) | 9.33 B |
| Working Capital | (108.38 M) | 1.48 B |
Note: Acquisition by Springstubb Brendan B of 5000 shares of Evolent Health at 8.75 subject to Rule 16b-3 [view details]
Evolent Health Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Evolent . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Evolent Health Buy or Sell Advice
When is the right time to buy or sell Evolent Health? Buying financial instruments such as Evolent Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Evolent Health in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Tech Growth Thematic Idea Now
Tech Growth
Instruments that are typically traded at high earnings multiples compared to their competitors and other sectors and have been known to drive market cycles frequently. The Tech Growth theme has 58 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Tech Growth Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Evolent Health Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more detail on how to invest in Evolent Stock please use our How to Invest in Evolent Health guide.You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Health Care Technology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evolent Health. If investors know Evolent will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evolent Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.81) | Revenue Per Share | Quarterly Revenue Growth 0.163 | Return On Assets | Return On Equity |
The market value of Evolent Health is measured differently than its book value, which is the value of Evolent that is recorded on the company's balance sheet. Investors also form their own opinion of Evolent Health's value that differs from its market value or its book value, called intrinsic value, which is Evolent Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evolent Health's market value can be influenced by many factors that don't directly affect Evolent Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Evolent Health's value and its price as these two are different measures arrived at by different means. Investors typically determine if Evolent Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evolent Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.